Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML

D. DiNardo, Courtney; Marvin‐Peek, Jennifer; Loghavi, Sanam; Takahashi, Koichi; C. Issa, Ghayas; Jen, Wei‐Ying; Daver, Naval; K. Reville, Patrick; J. Short, Nicholas; Sasaki, Koji; Mullin, Jillian; Bradley, Corey; Borthakur, Gautam; Maiti, Abhishek; Alvarado, Yesid; Pemmaraju, Naveen; A. Abbas, Hussein; Hammond, Danielle; Haddad, Fadi; Montalban‐Bravo, Guillermo; S. Chien, Kelly; Yılmaz, Musa; M. Kornblau, Steven; Jabbour, Elias; Ravandi, Farhad; M. Kadia, Tapan; Garcia‐Manero, Guillermo; Konopleva, Marina; M. Kantarjian, Hagop

doi:10.1200/jco-25-00640

Public

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML

Published in Journal of Clinical Oncology • Jun 13, 2025

Authors:

Courtney D. DiNardo

Jennifer Marvin‐Peek

Sanam Loghavi

Abstract

PURPOSE The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)–ineligible AML: venetoclax (VEN) in combination with hypomethylating agent (HMA) therapy and azaciti...

Subject

Isocitrate dehydrogenase

Venetoclax

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!